The Molecular Atlas / Hormone signaling
By Dissolv Labs · Published October 13, 2026 · Selected sources checked October 13, 2026
The direct answer
These names appear in growth-hormone research, but their studies cannot be pooled as if they describe one product. In particular, results for long-acting CJC-1295 do not automatically describe a listing labeled “No DAC.”
Evidence lens: Mixed models; molecule identity matters
The small label detail with a large consequence
A 2006 clinical paper studied long-acting CJC-1295 in two randomized, placebo-controlled, double-blind trials in healthy adults. Its questions concerned pharmacokinetics and growth hormone and IGF-1 responses over relatively short study periods. That is a specific preparation and a specific set of endpoints. Read the original CJC-1295 trials.
A catalog label saying “No DAC” should prompt an identity check before those results are cited. FDA's CJC review distinguishes forms with and without DAC and discusses which forms are represented in the available evidence. Read the named substance and chemical details, rather than relying on the shared CJC-1295 wording. See FDA's CJC substance review.
Why a hormone response is not a broad benefit claim
Measuring a change in circulating GH or IGF-1 can show a pharmacological response under the study conditions. It does not, by itself, establish better recovery, improved sleep, longer life or a favorable balance of benefits and harms. Each of those outcomes needs an appropriate study.
Also separate duration of a measured response from duration of a useful effect. A prolonged signal is a biological observation. Calling it better requires a defined objective and evidence that the objective was achieved safely.
Where ipamorelin and GHRP-2 enter the picture
A 1998 ipamorelin study used rat pituitary cells and animal experiments, including comparisons with other growth-hormone secretagogues. In the tested swine conditions, ipamorelin showed a different ACTH/cortisol response profile from GHRP-2 and GHRP-6. This is the context behind descriptions of selectivity in that paper. It is not proof of universal selectivity or a guarantee of safety in people. Read the original ipamorelin experiments.
What a useful comparison table should contain
- Exact identity: Record the full compound name, modification and form. A similar abbreviation is insufficient.
- Study population: Separate cultured cells, animal species and human participants.
- Measured endpoint: Write “GH concentration,” for example, rather than substituting a broad lifestyle outcome.
- Comparison and follow-up: Note the comparator, observation period and whether the experiment could detect meaningful harms.
These columns also expose a common problem with blend claims. Separate papers about two ingredients do not demonstrate what their combination does. A combined preparation creates another research question; it does not inherit every outcome from every ingredient paper.
Reading the linked catalog entries
The listings below help identify the named research materials. Their presence here is not a recommendation to combine or administer them. Use the exact specification and lot documentation when comparing a listing with a publication. If the form is unclear, that uncertainty should stay visible in the interpretation rather than being filled with an assumption.
Knowledge check: Can a trial of long-acting CJC-1295 establish the duration of a “No DAC” listing?
No. Verify the exact chemical form and preparation. Evidence about a modified long-acting molecule cannot automatically be transferred to a differently labeled material.
Keep exploring
- AOD9604 vs HGH Fragment 176–191: Similar Names, Separate Questions
- 5-Amino-1MQ: The Small Molecule Behind NNMT Research
- Try the interactive peptide lessons
Sources and scope
Educational synthesis of selected sources, prepared with AI assistance. This is not a systematic review or independent medical review. Product links are to Dissolv Labs’ own catalog. For corrections, contact Dissolv Labs and include the source and passage.
